Literature DB >> 11758674

Natural history of Fabry disease in males: preliminary observations.

R Schiffmann1.   

Abstract

A large cohort of patients with Fabry disease is being studied to determine the natural history of the disease and how this relates to the specific mutation involved and the amount of residual alpha-galactosidase A activity. To date, we have investigated the progression of cerebral lesions and stroke, as identified by magnetic resonance imaging, and renal disease. Results have shown that cerebral lesions do not appear until 23 years of age, but are present in all patients by 55 years of age. The peak onset of proteinuria occurred in the fourth decade, and the peak onset of chronic renal insufficiency and end-stage renal disease occurred in the fifth decade of life. Renal outcome was related to the type of mutation and residual enzyme activity. Data from these studies in untreated patients will be important when assessing the long-term efficacy of enzyme replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11758674     DOI: 10.1023/a:1012499119196

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  1 in total

1.  Quantitative analysis of cerebral vasculopathy in patients with Fabry disease.

Authors:  K E Crutchfield; N J Patronas; J M Dambrosia; K P Frei; T K Banerjee; N W Barton; R Schiffmann
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

  1 in total
  9 in total

1.  [Fabry's disease: new therapeutic options for this lysosomal storage disorder].

Authors:  A J Grau; M Schwaninger; H H Goebel; M Beck
Journal:  Nervenarzt       Date:  2003-05-20       Impact factor: 1.214

2.  Relationship of eNOS gene variants to diseases that have in common an endothelial cell dysfunction.

Authors:  Constantina Heltianu; Gabriela Costache; Anca Gafencu; Miheala Diaconu; Mihaela Bodeanu; Carmen Cristea; K Azibi; Livia Poenaru; Maya Simionescu
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

3.  Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

Authors:  B Hoffmann; A Garcia de Lorenzo; A Mehta; M Beck; U Widmer; R Ricci
Journal:  J Med Genet       Date:  2005-03       Impact factor: 6.318

4.  Co-existence of phenylketonuria and Fabry disease on a 3 year-old boy: case report.

Authors:  Daniela Concolino; Maria Rapsomaniki; Eliana Disabella; Simona Sestito; Maria G Pascale; Maria T Moricca; Giuseppe Bonapace; Elisea Arbustini; Pietro Strisciuglio
Journal:  BMC Pediatr       Date:  2010-05-17       Impact factor: 2.125

5.  Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry disease.

Authors:  G Altarescu; G Chicco; C Whybra; S Delgado-Sanchez; N Sharon; M Beck; D Elstein
Journal:  J Inherit Metab Dis       Date:  2008-01-05       Impact factor: 4.982

6.  CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy.

Authors:  L Jardim; L Vedolin; I V D Schwartz; M G Burin; C Cecchin; L Kalakun; U Matte; F Aesse; C Pitta-Pinheiro; J Marconato; R Giugliani
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 7.  Fabry disease in infancy and early childhood: a systematic literature review.

Authors:  Dawn A Laney; Dawn S Peck; Andrea M Atherton; Linda P Manwaring; Katherine M Christensen; Suma P Shankar; Dorothy K Grange; William R Wilcox; Robert J Hopkin
Journal:  Genet Med       Date:  2014-09-18       Impact factor: 8.822

8.  Prevalence of symptoms in female Fabry disease patients: a case-control survey.

Authors:  Machtelt G Bouwman; Saskia M Rombach; Erica Schenk; Annelies Sweeb; Frits A Wijburg; Carla E M Hollak; Gabor E Linthorst
Journal:  J Inherit Metab Dis       Date:  2012-03-20       Impact factor: 4.982

9.  Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.

Authors:  C M Eng; J Fletcher; W R Wilcox; S Waldek; C R Scott; D O Sillence; F Breunig; J Charrow; D P Germain; K Nicholls; M Banikazemi
Journal:  J Inherit Metab Dis       Date:  2007-03-08       Impact factor: 4.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.